Raymond James set a $10.00 target price on IMV (NYSE:IMV) in a report published on Thursday morning, BayStreet.CA reports. The brokerage currently has an outperform rating on the stock.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
A number of other brokerages have also recently commented on IMV. Wells Fargo & Co started coverage on IMV in a report on Monday, October 28th. They issued a market perform rating on the stock. HC Wainwright set a $11.50 target price on IMV and gave the stock a buy rating in a report on Monday, September 30th. Finally, Zacks Investment Research cut IMV from a buy rating to a hold rating in a report on Saturday, October 26th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $8.94.
Shares of NYSE IMV traded down $0.30 during midday trading on Thursday, hitting $2.58. 8,241 shares of the stock traded hands, compared to its average volume of 19,864. IMV has a one year low of $2.25 and a one year high of $7.07. The firm has a 50-day moving average of $2.74 and a two-hundred day moving average of $3.15.
IMV (NYSE:IMV) last announced its earnings results on Friday, November 8th. The company reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.03). The company had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.05 million.
A number of institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada raised its holdings in IMV by 3.6% in the 2nd quarter. Royal Bank of Canada now owns 98,676 shares of the company’s stock worth $288,000 after purchasing an additional 3,453 shares during the period. Morgan Stanley raised its holdings in IMV by 260.5% in the 2nd quarter. Morgan Stanley now owns 90,368 shares of the company’s stock worth $264,000 after purchasing an additional 65,300 shares during the period. Bank of Montreal Can raised its holdings in IMV by 17.5% in the 2nd quarter. Bank of Montreal Can now owns 88,889 shares of the company’s stock worth $260,000 after purchasing an additional 13,228 shares during the period. Hartford Financial Management Inc. raised its holdings in IMV by 9.6% in the 3rd quarter. Hartford Financial Management Inc. now owns 38,098 shares of the company’s stock worth $94,000 after purchasing an additional 3,348 shares during the period. Finally, Citadel Advisors LLC bought a new position in IMV in the 2nd quarter worth $37,000.
IMV Company Profile
IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Read More: How To Calculate Debt-to-Equity Ratio